Trisalus Life Sciences, INC Form 4 insider transactions

Director David J. Matlin reports acquisition of stock options in TriSalus Life Sciences, Inc.

Director Arjun J.J. Desai receives stock options in TriSalus Life Sciences, Inc.

Anil K. Singhal, a director of TriSalus Life Sciences, acquired stock options for 15,000 shares on August 13, 2024.

Andrew C. von Eschenbach, a director of TriSalus Life Sciences, acquired stock options for 15,000 shares on August 13, 2024.

Director Arjun Desai acquired 74,000 shares of TriSalus Life Sciences through a tender offer, exchanging warrants for common stock.

TriSalus Life Sciences finalizes its exchange offer and consent solicitation, issuing 2,110,366 common stock shares for tendered warrants.

TriSalus Life Sciences successfully concludes its warrant exchange offer and consent solicitation, amending the warrant agreement for public warrants but not for private placement or working capital warrants.

Director Andrew von Eschenbach transferred stock options to The Vons Living Trust but remains the beneficial owner.

TriSalus Life Sciences is offering to exchange outstanding warrants for common stock and seeking consent to amend the warrant agreement to reduce potential dilution and enhance financial flexibility.

Director Liselotte Hyveled of TriSalus Life Sciences, Inc. reports the acquisition of stock options on May 6, 2024.